A brand new nasal spray with the possible to fight COVID-19 along with other respiratory viral infections is going to be tested in the hopes associated with manufacturing it in Australia. The particular INNA-051 nasal treatment, produced by Australian biotech company Ena Respiratory, targets the primary web site of most respiratory infections, which includes COVID-19. Applied topically having a spray, the treatment activates the particular immune defence mechanisms within the respiratory tract. The technology may help fight SARS-CoV-2 and other bacterial infections like influenza and the typical cold. The federal government announced upon Nov 22 that and also a private partner it would supply $11. 7 million (US$8. 5 million) to fund therapy, as part of the Biomedical Translation Account. If tests are profitable, the product will be manufactured in Sydney. Other projects to receive the cash boost from the finance target conditions including autoimmune diseases and neurological problems. Elsewhere, newly-funded systems aim to help patients make sure to take medications…